Statement of Robert K. Coughlin, President & CEO of MassBio, on the House’s Proposal to Repeal the Orphan Drug Tax Credit
“The Orphan Drug Tax Credit has been instrumental in helping to finance the development of lifesaving treatments for patients with rare diseases, and any effort to dismantle it would be a major blow to patients around the world for which there is still no hope of treatment. With roughly 30 million Americans still waiting for even one viable treatment for their rare disease, any regression in bringing lifesaving therapies to them is unacceptable. We must continue to incentivize the research coming out our top research hospitals, universities and biopharmaceutical companies to ensure that future generations have access to lifesavings drugs.”
MassBio also signed the following letter from the Council of State Bioscience Associations (CSBA) in support of the ODTC.